Recent Press Releases

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION PLEGRIDYTM Approved in the US and EU for Multiple Sclerosis ELOCTATETM Launched in the US for Hemophilia A Rollout of...

Roche invests for the future in its Basel site

Roche invests for the future in its Basel site Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.

Amgen Statement Regarding Third Point Investment

THOUSAND OAKS, Calif., Oct.

FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted...

ACTELION DELIVERS STRONG NINE MONTHS RESULTS

ACTELION DELIVERS STRONG NINE MONTHS RESULTS ALLSCHWIL/BASEL, SWITZERLAND - 21 October 2014 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2014. PRODUCT...

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND NORTH CHICAGO, Ill., Oct. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized...

Shire plc: AbbVie Terminates Offer for Shire

Shire plc: AbbVie Terminates Offer for Shire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 20, 2014

Lilly Declares Fourth-Quarter 2014 Dividend

INDIANAPOLIS, Oct.

Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 20, 2014

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date

New Large-Scale Study Will Look at How Nutrition Can Help Keep Patients from Returning to the Hospital

Advocate Health Care and Abbott Will Conduct Study on 3,000 Adult Patients to Quantify the Effectiveness of Nutrition Care in Hospital Settings

ABBOTT PARK, Ill.,

EPILEPSY PATIENT ADVOCACY GROUPS URGE PASSAGE OF DEA SCHEDULING LEGISLATION

EPILEPSY PATIENT ADVOCACY GROUPS URGE PASSAGE OF DEA SCHEDULING LEGISLATION WASHINGTON – A group of 15 epilepsy patient organizations sent a letter to congressional leaders urging them to pass...

New resource on health coverage, Highlights hurdles patients may face accessing needed medicines

New resource on health coverage, Highlights hurdles patients may face accessing needed medicines Washington, D.C. (October 14, 2014) — Today, the Pharmaceutical Research and Manufacturers of...

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study TARRYTOWN, N.Y., Oct....

FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic

FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic The U.S. Food and Drug Administration today approved new labeling for Embeda (morphine sulfate and...

Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results

10/20/2014 LAVAL, Quebec, Oct. 20, 2014 /PRNewswire/ -- 2014 Third Quarter Results Total Revenue $2.1 billion; an increase of 33% over the prior year Total same store sales organic growth...

FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII

FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII EMBEDA is the first and only approved ER morphine specifically...